Clinical Trial: This Study Will Evaluate the Effect and Safety of 626 in Patients With CLE

U.S., Oct. 29 -- ClinicalTrials.gov registry received information related to the study (NCT07900867) titled 'This Study Will Evaluate the Effect and Safety of 626 in Patients With CLE' on Oct. 21.

Brief Summary: This study aims to evaluate the efficacy and safety of subcutaneous (SC) 626 versus placebo in adult participants with cutaneous lupus erythematosus (CLE).

Study Start Date: Nov., 2026

Study Type: INTERVENTIONAL

Condition: Cutaneous Lupus Erythematosus (CLE)

Intervention: DRUG: Placebo

Placebo subcutaneous (SC) injection

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Published by HT Digital Content Services with permission from Health Daily Digest....